Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
58%
Antiretroviral Therapy
42%
HIV Transmission
21%
Early Antiretroviral Therapy
13%
HIV Reservoir
12%
Reservoir Size
12%
Latent Reservoir
11%
People Living with HIV (PLHIV)
11%
Highly Active Antiretroviral Therapy (HAART)
10%
HIV DNA
10%
Viremia
10%
Perinatal Infection
10%
United States
10%
Resting CD4+ T Cells
10%
Nevirapine
9%
Remission
8%
Viral Reservoir
8%
Virus
8%
HIV Cure
8%
Immune Activation
7%
CD4+ T Cells
7%
AIDS/HIV
7%
Viral Load
7%
Cabotegravir
7%
Pharmacokinetics
7%
Older Adults
7%
Proviral Reservoirs
7%
Antiretroviral
6%
HIV RNA
6%
Neonate
6%
T Cells
6%
Early Treatment
5%
HIV Infection
5%
African children
5%
Latent HIV Reservoir
5%
Combined Antiretroviral Therapy (cART)
5%
HIV Patients
5%
Proof of Concept Study
5%
Infected children
5%
Human Immunodeficiency Virus Infection
5%
Virologic Control
5%
Low-level Viremia
5%
Cisgender
5%
Combination Therapy
5%
Single Center
5%
Scientific Strategies
5%
Support Initiatives
5%
Breastfeeding Support
5%
Human Immunodeficiency Virus Prevention
5%
DNA Decay
5%
Immunology and Microbiology
Human Immunodeficiency Virus 1
89%
Human Immunodeficiency Virus
68%
Blood Plasma
24%
Drug Resistance
20%
T-Helper Cell
20%
Viremia
19%
Human Immunodeficiency Virus Infection
14%
Viral Load
13%
Reverse Transcriptase
11%
Genotype
10%
Dynamics
10%
Monospecific Antibody
7%
Cytokine
7%
Virus Type
7%
Provirus
6%
T Cell
6%
Wild Type
6%
CD4
5%
Lymphocyte Transformation
5%
COVID-19
5%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
34%
Infection
21%
Human Immunodeficiency Virus Infection
17%
Human Immunodeficiency Virus 1
17%
Highly Active Antiretroviral Therapy
14%
Viremia
13%
Drug Resistance
13%
T-Helper Cell
12%
Nevirapine
12%
Pediatrics
9%
Aciclovir
9%
Adolescent
8%
Resistance Mutation
7%
Cabotegravir
7%
Genotype
6%
Proteinase Inhibitor
6%
Biological Marker
5%
Treatment Interruption
5%
Arm
5%
Transgender
5%
Cerebrospinal Fluid
5%
Serositis
5%
COVID-19
5%